Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
Diabetic retinopathy (DR) is the damage caused to the blood vessels in the retina by diabetes mellitus. There are two types of this condition, namely, non-proliferative and proliferative or progressed DR. It is caused by changes in blood glucose levels, which cause abnormal growth of the light-sensitive tissues in the eye. The common symptoms include dark spots or floating strings in the vision field, blurred or fluctuating vision, impaired colour vision, or vision loss.
Growing Cases of Diabetes Augmenting the Market Growth
Diabetes causes damage to the eyes, thus, the growing cases of diabetes among the world population are expected to accelerate market growth. The favourable government policies to make advanced healthcare services available to the masses and extensive research and development activities are likely to generate various new opportunities that will impact diabetic retinopathy treatment market value in the forecast period. Additionally, the expansion of healthcare infrastructure and the rising demand for early detection technologies are some of the other driving factors for the DR treatment market. The clinical pipeline for DR seems full of promises, with lots of drugs under the umbrella specifically targeting diabetic retinopathy among diabetic patients. Moreover, technological advancements in ophthalmic surgical and diagnostic instruments will aid the growth of the diabetic retinopathy treatment market during the forecast years.
Regulatory Approvals to Meet Rising Diabetic Retinopathy Treatment Market Demand
The market is witnessing significant regulatory approvals by the authorities including the FDA. For instance, in April 2024, AEYE Health, the leading company for AI retinal imaging and diagnostics, received the first-ever FDA clearance for a fully autonomous artificial intelligence (AI) capable of diagnosing referable diabetic retinopathy from retinal images obtained by a handheld camera.
This new FDA clearance is based on two large-scale prospective phase-III studies, in which AEYE-DS demonstrated best-in-class efficacy and imageability.
According to the estimates by the CCD’s Vision and Eye Health Surveillance System, there were an estimated 9.6 million people in the United States suffering from diabetic retinopathy (DR) in 2021. This new device is a combination of a fully autonomous AI with a portable handheld device, bringing a new and affordable screening solution to address enabling increasing early detection rates and driving retinopathy management in the market. These advancements contribute to the market's growth by addressing a critical need for efficient, accessible screening solutions.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Technologically Advanced Diagnostics
The market is witnessing an increasing integration of AI-powered diagnostic solutions that are artificially intelligent for the early detection of the condition resulting in improved accuracy, accessibility, and efficiency in remote areas.
Increasing Research and Development Activities Poised to Bring Potent Treatment Options
The researchers are highly active and continuously exploring new potential treatments to treat several diseases associated with diabetes including diabetic retinopathy. For instance, some researchers at the University of Oklahoma Health Sciences and Memorial Sloan Kettering (MSK) Cancer Center are exploring a new, revolutionary treatment to know how anti-ceramide immunotherapy can address the root cause of the disease and stop the progression toward blindness at an earlier stage than previous treatments. This could positively impact the prognosis of patients suffering from diabetic retinopathy, and potentially bring a new treatment option into the market, propelling market growth.
Rise of Combination Therapies to Impact the Diabetic Retinopathy Treatment Market Value
Combination therapies are gaining traction as they increase the efficacy of the treatment. The growing trend toward integrating ant-VEGF drugs with steroids or other treatments is expected to influence the market size in the coming years. Biologic drugs and novel treatment modalities, like gene therapy and anti-VEGF injections, are gaining traction for their targeted and effective treatment of diabetic retinopathy. The improved efficacy and safety profiles of these advanced therapies are expected to dominate the market, contributing to improved patient outcomes.
Rising Regulatory Approvals
Regulatory bodies are fast-tracking approvals for innovative diagnostic tools and therapies, enabling quicker commercialisation of innovative technologies, and enhancing access to early-stage detection and personalised treatments.
Market Breakup by Indication
Market Breakup by Treatment Type
Market Breakup by End User
Market Breakup by Region
Market Share by Indication to Witness Substantial Growth
Based on Indication, the market is divided into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy NPDR segment leads the market share due to the higher prevalence which is the prior stage of diabetic retinopathy. It is commonly asymptomatic but can progress to vision-threatening conditions if untreated, making early diagnosis and treatment crucial. This contributes to the high demand for therapies such as anti-VEGF injections and laser treatments compared to proliferative diabetic retinopathy (PDR).
The United States is expected to lead the market due to the high market penetration of anti-VEGF drugs such as Eylea, Avastin, and Lucentis. The market is also expected to grow in the region owing to the supportive reimbursement policies and the increasing prevalence of diabetes. The increasing awareness regarding the availability of advanced options for treating diabetic retinopathy also adds to the regional market growth. The market is driven by the availability of modern healthcare infrastructure, favourable government initiatives about medication research, and high patient and practitioner awareness levels.
On the other hand, the Japanese market is expected to expand at a significant growth rate because of the surging geriatric population, high healthcare expenditure, large patient pool, innovation in diagnostic approaches, government health insurance policies, and rising disposable income. Diabetes is affecting a huge number of geriatric populations in India post-COVID-19, which is propelling the diabetic retinopathy treatment market in the region.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Alimera Sciences, Inc.
Founded in 2003 and headquartered in Atlanta, Georgia, Alimera Sciences is a biopharmaceutical company focused on the development and commercialisation of prescription ophthalmic pharmaceuticals. Their portfolio includes ILUVIEN® , a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME). The company provides innovative treatments for retinal diseases, especially with affected vision.
Genentech, Inc.
Established in 1976 and based in South San Francisco, California, Genentech, Inc. is a biotechnology pioneer and a member of the Roche Group. The company has a significant presence in the market. The company portfolio includes Lucentis, a treatment for diabetic retinopathy and age-related macular degeneration. The company is focused on developing cutting-edge solutions for serious medical conditions, particularly in oncology, immunology, and ophthalmology.
KalVista Pharmaceuticals, Inc.
Founded in 2004 and headquartered in Cambridge, Massachusetts, KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on small molecule drugs for diseases with significant unmet needs. Their portfolio includes treatments for diabetic macular edema (DME) and hereditary angioedema (HAE). The company is committed to developing innovative treatments that address conditions impacting quality of life.
Opthea Limited
Established in 2001 and based in Melbourne, Australia, Opthea Limited is a clinical-stage biopharmaceutical company specializing in the development of therapies for treating eye diseases. Opthea is focused on advancing treatments that improve vision outcomes for patients with retinal disorders.
Oxurion NV
Founded in 1956 and headquartered in Leuven, Belgium, Oxurion NV is a biopharmaceutical company dedicated to developing novel treatments for back-of-the-eye diseases, particularly diabetic macular edema (DME) and diabetic retinopathy.
Other key players in the market include Kubota Pharmaceutical Holdings Co., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Bayer AG, Allergan Plc., and ThromboGenics NV.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
In 2023, the global attained a value of nearly USD 6.49 billion.
The market is projected to grow at a CAGR of 6.70% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 11.63 billion by 2032.
The major drivers of the market include the large patient pool, rising disposable income, favourable government policies, extensive research and development activities, expansion of healthcare infrastructure, rising demand for early detection technologies, and technological advancements.
Growing cases of diabetes and rising global geriatric population are the key market trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types of diabetic retinopathy treatments are proliferative diabetic retinopathy and non-proliferative diabetic retinopathy.
Based on treatment type, the market is divided into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy.
The end uses of the market include hospitals, ophthalmic clinics, and ambulatory surgical centres.
The major players in the market are ALIMERA SCIENCES, INC., Genentech, Inc., KalVista Pharmaceuticals, Inc., Opthea Limited, Oxurion NV, and Kubota Pharmaceutical Holdings Co., Ltd., among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Indication |
|
Breakup by Treatment Type |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Pricing Plans
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-120-433-0800
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124